Clinical Research Directory

Inclusion Criteria: * Starting treatment with monoclonal antibodies: nivolumab, pembrolizumab ipilimumab, bevacizumab, trastuzumab, durvalumab or atezolizumab. * 18 years and older. * No known history of increased susceptibility to immunological reactions. * Subject is able and willing to sign the Informed Consent Form prior to screening evaluations. Exclusion Criteria: * Other research medication within 4 weeks of the start of the study. * Inclusion in medical research in which the administration of medication should follow its stated times and dosages of infusions * Dosage deviates from standard protocol * Patients whom receive drugs through a central venous catheter (and for example porth-a-cath).